Highest-materiality recent filing
Astrana Health Q1 revenue up 56% to $965M; adjusted EBITDA up 82% to $66.3M
Total revenue $965.1M, up 56% YoY; Care Partners revenue $909.7M, up 51%.
Astrana Health expects material weakness in internal controls; 10-K filing by extension deadline
Updated investor presentation furnished; no specific new financial or strategic details.
FY2025 total revenue $3.18B (+56% YoY); at high end of guidance; Care Partners revenue $3.02B (+55%).
Astrana Health Q3 revenue $956M (+100% YoY); adjusted EBITDA $68.5M; closes Prospect Health
Total revenue $956.0M, up 100% YoY; Care Partners revenue $897.7M, up 97%.
Acquired PHP Holdings reports FY2024 net loss of $78.7M on $1.19B revenue; high leverage
PHP Holdings net loss $78.7M in FY2024 vs net income $30.5M in FY2023, driven by $138.3M interest expense.
Astrana Health Q2 revenue $654.8M, +35% YoY; adjusted EBITDA $48.1M, guidance reiterated
Total revenue $654.8M, up 35% from $486.3M; adjusted EBITDA $48.1M, both at higher end of guidance.
Astrana closes Prospect Health acquisition for $708M, updates FY 2025 guidance
Purchase price reduced from $745M to $708M; closed July 1, 2025.
Astrana Health Q1 revenue up 53% to $620M; net income down to $6.7M
Total revenue $620.4M (+53% YoY); Care Partners revenue $601M (+57%).
Astrana Health enters $1.295B credit facility; $745M delayed draw for Prospect acquisition
Five-year $300M revolver, $250M term A loan, and $745M delayed draw term loan.
Astrana Health FY2024 revenue up 47% to $2.03B, net income down 29% to $43.1M
Total revenue $2,034.5M (+47% YoY); Care Partners revenue $1,949.0M (+52%).
Astrana Health: Prospect Medical Ch. 11 filing excludes acquisition assets; deal unaffected
Prospect Medical Holdings filed for Chapter 11 bankruptcy on January 11, 2025, in the Northern District of Texas.
Astrana Health to acquire Prospect Health for $745M; adds ~610k members
Purchase price of $745 million plus assumption of certain liabilities; expected close mid-2025 subject to regulatory approval.
Astrana Health to acquire hospital, health plan & ACO for $745M; arranges $1.195B financing
Acquires equity of Prospect Health Plan, Alta Newport Hospital (Foothill Regional), and Prospect ACO Rhode Island for $745M.
Astrana Health Q3 revenue up 37% to $478.7M; net income down 27% to $16.1M
Q3 net income $16.1M (-27% YoY); diluted EPS $0.33 (-30%); adjusted EBITDA $45.2M (-13%).
Astrana Health Q2 revenue up 40% to $486.3M, EPS $0.40; acquires CHS from Centene
Q2 revenue $486.3M (+40% YoY), net income $19.2M (+46%), diluted EPS $0.40 (+43%), adjusted EBITDA $47.9M (+34%).
Purchase price $37.5M plus earnout up to $21.5M for CHS, GTPA, and HPN.
Astrana Q1 revenue $404.4M (+20% YoY), net income $14.8M (+13%), EPS $0.31
Total revenue $404.4M (+20% YoY); net income attributable $14.8M (+13%); diluted EPS $0.31 (+11%).
Astrana Health amends CEO & COO/CFO employment pacts, grants $13M in equity
CEO Brandon Sim new base salary $850k, target bonus 125%; CFO Chandan Basho base $600k, target bonus 80%.
Astrana Health completes acquisitions of AHMS and 25% of I Health; purchase agreements amended
Completed second closing on March 31, 2024, acquiring all partnership interests of Advanced Health Management Systems (AHMS).
Astrana Health issues FY2024 revenue $1.65-1.85B, Adj. EBITDA $165-185M
FY2023 rev $1.39B, Adj. EBITDA $146.6M, diluted EPS $1.29.
Astrana Health FY2023 revenue $1.39B (+21%), net income $60.7M (+34%), EPS $1.29 (+30%)
Total revenue $1,386.7M, up 21% from $1,144.2M in 2022.
Apollo Medical Holdings completes first closing of CFC asset acquisition; amends purchase agreement
First closing for CFC assets completed Jan 31, 2024; second closing for AHMS expected Q1 2024.
On May 7, 2026, Dinesh Kumar, M.D., the Chief Medical Officer of Astrana Health, Inc. (the “Company”), notified the Company of his intention to resign, effective as of June 1, 2026.
On March 26, 2025, Astrana Health, Inc. (the “Company”) appointed Glenn W. Sobotka as the Company’s Chief Accounting Officer and principal accounting officer, effective March 26, 2025
John Vong, the Company’s current Chief Accounting Officer and principal accounting officer, will transition to a new role at the Company and will no longer serve as the principal accounting officer as of the Effective Date.
Effective April 23, 2024, Dr. Albert Young transitioned from his position as Chief Administrative Officer of Astrana Health, Inc. (the “Company”) to a new role as Senior Vice President of Health Affairs of the Company.
· Chandan Basho, previously Chief Financial Officer and Chief Strategy Officer, was appointed Chief Financial Officer and Chief Operating Officer.
· Thomas S. Lam, M.D., M.P.H., previously Co-Chief Executive Officer and President and a director, was appointed Vice Chairman of the Board;
· Brandon Sim, previously Co-Chief Executive Officer, was appointed Chief Executive Officer and President;
On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer.
On February 2, 2023, Michael Eng notified the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”) of his decision to resign as a member of the Board effective as of February 15, 2023.
On November 30, 2022, Apollo Medical Holdings, Inc. (together with its subsidiaries and affiliated entities, “Company”) appointed John Vong as the Company’s Chief Accounting Officer.
In connection with the appointment, Eric Chin will step down for personal reasons as Chief Financial Officer effective May 5, 2022.
On May 5, 2022, the Company appointed Chan Basho as the Company's Interim Chief Financial Officer, effective May 5, 2022.
Max materiality 0.85 · Median 0.50 · Most common event other_material